凯莱英(002821) - 2023 Q1 - 季度财报

Financial Performance - The company achieved total revenue of CNY 2.25 billion in Q1 2023, representing a year-on-year increase of 9.09%[6] - Net profit attributable to shareholders reached CNY 630.35 million, up 26.22% compared to the same period last year[6] - The net profit excluding non-recurring items was CNY 617.64 million, reflecting a growth of 26.98% year-on-year[6] - Cash flow from operating activities surged to CNY 1.30 billion, a significant increase of 537.09% compared to the previous year[6] - The gross profit margin improved to 48.40%, an increase of 3.16 percentage points from the previous year, with gross profit amounting to CNY 1.09 billion[12] - Revenue from the small molecule CDMO business was CNY 2.00 billion, a year-on-year increase of 4.31%, with a 45.37% growth when excluding large orders[13] - Emerging business revenue reached CNY 249 million, marking a substantial growth of 72.54% year-on-year[14] - Total operating revenue for Q1 2023 reached ¥2,249,034,497.62, an increase of 9.1% compared to ¥2,061,708,856.14 in Q1 2022[24] - Operating profit for Q1 2023 was ¥709,948,636.92, up 24.5% from ¥570,097,662.75 in the same period last year[24] - Net profit attributable to shareholders for Q1 2023 was ¥630,346,004.43, compared to ¥499,398,084.81 in Q1 2022, reflecting a growth of 26.2%[25] - Basic and diluted earnings per share for Q1 2023 were both ¥1.72, an increase from ¥1.36 in Q1 2022[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 18.55 billion, a 1.69% increase from the end of the previous year[6] - Total current assets amount to ¥11,977,491,343.33, an increase from ¥11,860,458,372.35 at the beginning of the year[21] - Total liabilities decreased to ¥2,176,785,958.74 in Q1 2023 from ¥2,544,270,867.15 in Q1 2022, a reduction of approximately 14.5%[24] - Total equity attributable to shareholders increased to ¥16,324,854,569.41 in Q1 2023, up from ¥15,647,427,643.90 in Q1 2022, representing an increase of 4.3%[24] - The total liabilities and equity combined amounted to ¥18,546,760,048.14 in Q1 2023, compared to ¥18,239,273,651.93 in Q1 2022[24] Cash Flow - The cash inflow from operating activities for Q1 2023 was CNY 2,861,189,791.85, an increase of 48.8% compared to CNY 1,925,864,058.95 in Q1 2022[28] - The net cash flow from operating activities reached CNY 1,303,525,263.66, significantly up from CNY 204,607,061.83 in the same period last year[28] - Cash inflow from investment activities totaled CNY 8,399,828,818.08, compared to CNY 611,137,118.87 in Q1 2022, marking a substantial increase[28] - The net cash outflow from investment activities was CNY 327,218,213.85, an improvement from a net outflow of CNY 1,131,790,662.67 in Q1 2022[28] - The cash flow from financing activities showed a net inflow of CNY 383,841,586.32, with cash outflow for dividend payments recorded at CNY 3,889,772.50[29] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 5,379,198,112.41, down from CNY 5,642,739,406.29 at the end of Q1 2022[29] - The company reported a cash inflow from the recovery of investments of CNY 8,368,856,153.32, a significant increase from CNY 607,807,000.00 in the previous year[28] - The cash outflow for purchasing goods and services was CNY 638,798,212.57, a decrease from CNY 1,003,677,026.11 in Q1 2022[28] - The total cash inflow from operating activities was CNY 2,861,189,791.85, while total cash outflow was CNY 1,557,664,528.19, resulting in a net cash flow of CNY 1,303,525,263.66[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 73,675[16] - ASYMCHEM LABORATORIES, INCORPORATED holds 31.12% of shares, totaling 115,133,168 shares[16] - HAO HONG holds 3.86% of shares, totaling 14,268,699 shares[16] - The company repurchased a total of 5,229,266 shares, accounting for 1.4134% of the total A+H share capital[18] - The company has not completed the transfer procedures for the employee stock ownership plan as of the end of the reporting period[19] Research and Development - Research and development expenses for Q1 2023 were ¥162,096,744.48, compared to ¥130,883,695.56 in Q1 2022, indicating a rise of 23.8%[24] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[23] Market Expansion - The company plans to expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements[12]